Interferon alfa-2b (Merck Sharp & Dohme)

干扰素α-2b（默沙东）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameInterferon alfa-2b (Merck Sharp & Dohme)
Drug Alias NameAlfratronolDepoInterferon alpha甘乐能Intron AViraferon +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsSkin MelanomaBurnsCicatrix, Hypertrophic +[18] 
Global Approved IndicationsMultiple MyelomaCarcinoma, Renal CellMelanoma +[13] 
Approved Indications in ChinaMelanomaLymphoma, FollicularLeukemia, Hairy Cell +[6] 
Original Approved Country/TerritoryUnited States
Original Approved Date1986/06/04
Country/TerritoryCanadaUnited StatesSouth Africa +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesScheringMerck Sharp & Dohme CorpSchering-Plough Ltd +[4] 
Inactive CompaniesSchering-PloughUniversity Of AlbertaMerck Sharp & Dohme Bv +[7] 
Active IndicationsSkin MelanomaMultiple MyelomaCarcinoma, Renal Cell +[11] 
Inactive IndicationsBurnsCicatrix, HypertrophicKidney Neoplasms +[7] 

Other Information

ATC CodeL03AB05
Related LinksWikipediaDrugBankKEGG